Washington is currently home to 1780 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Vancouver. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
NCT05137054
Recruiting
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again. In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evid... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: VA Puget Sound Health Care System, Seattle, Washington
Conditions: Multiple Myeloma
Register for Updates
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
NCT04663308
Recruiting
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.
Gender:
All
Ages:
12 years and above
Trial Updated:
06/13/2024
Locations: University of Washington - Harborview Medical Center, Seattle, Washington
Conditions: Primary Sclerosing Cholangitis
Register for Updates
Pain and Opioids: Integrated Treatment In Veterans
NCT04648228
Recruiting
This trial will recruit veterans with chronic pain (N = 160) who are prescribed buprenorphine for the treatment of opioid use disorder (OUD). We seek to: (1) examine the efficacy of an integrated treatment to reduce pain interference and substance misuse (Acceptance and Commitment Therapy and Mindfulness-Based Relapse Prevention [ACT + MBRP]) compared to an education control (EC) consisting of a protocol-based series of education sessions concerning chronic pain, opioids, and buprenorphine use a... Read More
Gender:
All
Ages:
Between 21 years and 75 years
Trial Updated:
06/13/2024
Locations: Puget Sound VA Healthcare System, Tacoma, Washington
Conditions: Chronic Pain, Opioid-use Disorder, Opioids; Harmful Use
Register for Updates
Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations
NCT04641442
Recruiting
This study is a Phase 2 trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in patients with NLRC4-GOF, XIAP deficiency, or CDC42 mutations.
Gender:
All
Ages:
All
Trial Updated:
06/13/2024
Locations: Seattle Children´s Hospital, Seattle, Washington
Conditions: NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
Register for Updates
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
NCT04637763
Recruiting
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: Swedish Cancer Institute, Seattle, Washington
Conditions: Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
Register for Updates
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
NCT04589650
Recruiting
This is a prospective Phase II multi-center study with an upfront 16-week, randomized, double-blind, placebo-controlled period, and extension periods, to assess the efficacy, safety and pharmacokinetics of alpelisib in pediatric and adult participants with PIK3CA-related overgrowth spectrum (PROS).
Gender:
All
Ages:
2 years and above
Trial Updated:
06/13/2024
Locations: Childrens Hosp and Regional Med Ctr, Seattle, Washington
Conditions: PIK3CA-related Overgrowth Spectrum (PROS)
Register for Updates
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
NCT04534205
Recruiting
An open-label, controlled, multi-site, interventional, 2-arm, Phase II trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing programmed cell death ligand -1 (PD-L1) with combined positive score (CPS) ≥1. This trial has two parts. Part A, an initial non-randomized Safety Run-In Phase to confirm the safety and tolerability at the selected dose range level of BNT113 in co... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: MultiCare Regional Cancer Center, Tacoma, Washington
Conditions: Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Register for Updates
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT03488693
Recruiting
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Gender:
Female
Ages:
35 years and above
Trial Updated:
06/13/2024
Locations: MultiCare Auburn Medical Center, Auburn, Washington
Conditions: Breast Cancer
Register for Updates
Product Surveillance Registry
NCT01524276
Recruiting
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.
Gender:
All
Ages:
All
Trial Updated:
06/13/2024
Locations: Not set, Bremerton, Washington
Conditions: Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders, Digestive Disorders, Intracranial Aneurysm, Mechanical Circulatory Support, Respiratory Therapy, Aortic, Peripheral Vascular and Venous Disorders, Minimally Invasive Surgical Procedures, Diagnostic Techniques and Procedures, Surgical Procedures, Operative, Renal Insufficiency, Neurovascular, Coronary Artery Disease, Ear, Nose and Throat Disorder
Register for Updates
DePTH: De-emphasize PTH
NCT06288451
Recruiting
The De-emphasize Parathyroid Hormone (DePTH) Study is a 12-month pragmatic, randomized, parallel-group, active comparator, open-label, blinded end-point study of 90 patients with incident or prevalent secondary hyperparathyroidism and kidney failure treated with in-center hemodialysis. It tests the hypothesis that low fixed-dose oral calcitriol (intervention) will have more favorable effects on a comprehensive panel of biomarkers that assesses mineral metabolism, bone turnover, and serum calcifi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: University of Washington, Seattle, Washington
Conditions: Kidney Failure, Chronic, Chronic Kidney Disease-Mineral and Bone Disorder
Register for Updates
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
NCT06113328
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of MK-6194 in participants with non-segmental vitiligo. The primary hypothesis is that at least 1 MK-6194 dose is superior to placebo with regards to percent change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/12/2024
Locations: Dermatology Specialists of Spokane ( Site 0126), Spokane, Washington
Conditions: Non-segmental Vitiligo
Register for Updates
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
NCT05922761
Recruiting
The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS). The name of the study drugs involved in this study are: Belumosudil (an immunotherapy) Fluticasone (an intranasal corticosteroid) Azithromycin (an antibiotic) Montelukast (a leukotriene receptor antagonist) Prednisone (a c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: Fred Hutchinson Cancer Center, Seattle, Washington
Conditions: Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases, Chronic Graft Versus Host Disease
Register for Updates